Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.98 USD
+0.03 (3.53%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.99 +0.01 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LCTX 0.98 +0.03(3.53%)
Will LCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for LCTX
LCTX: Analyst Jason Kolbert from D. Boral Capital Maintains Buy Rating | LCTX Stock News
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business ...
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...
Lineage Cell Therapeutics doses first patient in DOSED study
BlackRock, Inc. Significantly Reduces Holdings in Lineage Cell Therapeutics Inc